ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2024

A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).

Yushi Hirota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.